Literature DB >> 3891303

Prodrugs. Do they have advantages in clinical practice?

V J Stella, W N Charman, V H Naringrekar.   

Abstract

Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug. The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.

Mesh:

Substances:

Year:  1985        PMID: 3891303     DOI: 10.2165/00003495-198529050-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  62 in total

1.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

Review 2.  The long-acting neuroleptics: a retrospective appraisal.

Authors:  H L Yale
Journal:  Drug Metab Rev       Date:  1978       Impact factor: 4.518

3.  Rate studies on dissolution and enzymatic hydrolysis of chloramphenicol palmitate.

Authors:  H Andersgaard; P Finholt; R Gjermundsen; T Hoyland
Journal:  Acta Pharm Suec       Date:  1974-06

4.  Chemical modification of clindamycin: synthesis and evaluation of selected esters.

Authors:  A A Sinkula; W Morozowich; E L Rowe
Journal:  J Pharm Sci       Date:  1973-07       Impact factor: 3.534

5.  Parenteral and oral clindamycin therapy in surgical infections: a preliminary report.

Authors:  H T Edmondson
Journal:  Ann Surg       Date:  1973-11       Impact factor: 12.969

6.  Drug latentiation. Synthesis and preliminary evaluation of testosterone derivatives.

Authors:  S M Kupchan; A F Casy; J V Swintosky
Journal:  J Pharm Sci       Date:  1965-04       Impact factor: 3.534

7.  Macromolecular residues contributing to the allergenicity of penicillins and cephalosporins.

Authors:  G T Stewart
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

8.  Targeting of drugs.

Authors:  G Gregoriadis
Journal:  Nature       Date:  1977-02-03       Impact factor: 49.962

Review 9.  Prodrugs and site-specific drug delivery.

Authors:  V J Stella; K J Himmelstein
Journal:  J Med Chem       Date:  1980-12       Impact factor: 7.446

10.  Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma.

Authors:  A I Mandell; F Stentz; A E Kitabchi
Journal:  Ophthalmology       Date:  1978-03       Impact factor: 12.079

View more
  28 in total

Review 1.  Determinants of passive drug entry into the central nervous system.

Authors:  M D Habgood; D J Begley; N J Abbott
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

Review 2.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

Review 3.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 4.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

5.  Synthesis of a long acting nanoformulated emtricitabine ProTide.

Authors:  Dhruvkumar Soni; Aditya N Bade; Nagsen Gautam; Jonathan Herskovitz; Ibrahim M Ibrahim; Nathan Smith; Melinda S Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson J Edagwa
Journal:  Biomaterials       Date:  2019-08-20       Impact factor: 12.479

Review 6.  Pharmacokinetic considerations in rational drug design.

Authors:  M Gumbleton; W Sneader
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

7.  Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective beta-adrenoceptor blocker in asthmatic subjects.

Authors:  K G Bauer; F Brunner-Ferber; L M Distlerath; E A Lippa; B Binkowitz; P Till; G A Kaik
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

8.  Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection.

Authors:  Laszlo Prokai; Katalin Prokai-Tatrai; Pal Perjesi; Alevtina D Zharikova; Evelyn J Perez; Ran Liu; James W Simpkins
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

9.  Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds.

Authors:  O H Chan; H L Schmid; L A Stilgenbauer; W Howson; D C Horwell; B H Stewart
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

10.  Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol.

Authors:  Eric A Harris; David A Lubarsky; Keith A Candiotti
Journal:  Ther Clin Risk Manag       Date:  2009-12-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.